文献速递甲状腺疾病

MEN2A中的甲状腺髓样癌:ATA中危或高危RET突变并不预测疾病侵袭性

Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该回顾性队列研究纳入262例携带中危或高危胚系RET突变的甲状腺髓样癌患者,比较两组总生存和远处转移时间。结果显示高危与中危突变患者的总生存(P=0.40)和远处转移发生(P=0.33)均无显著差异,多变量分析中高危突变与总生存无关(P=0.40)。作者认为两者临床病程侵袭性相似,建议未来指南按发病早晚而非风险高低对RET突变分类。

要点

  • 高危与中危RET突变患者的甲状腺髓样癌总生存无显著差异(P=0.40)。
  • 两组远处转移发生无显著差异(P=0.33),仅诊断时N1状态与远处转移显著相关(HR 2.10)。
  • 作者建议未来指南按发病早晚而非风险高低对RET突变分类。

核心结论

  • 高危与中危RET突变患者在甲状腺髓样癌诊断后总生存和远处转移发生相似,临床病程侵袭性相似。
  • 高危意味着疾病侵袭性增加,因此未来指南应考虑按发病早晚而非风险高低对RET突变分类。

研究设计与样本

  • 回顾性队列研究,使用机构性2型多发性内分泌腺瘤病登记数据库。
  • 三级癌症诊疗中心开展。
  • 纳入携带中危或高危胚系RET突变的甲状腺髓样癌患者,共127例中危和135例高危(n=262)。
  • 观察性研究,无干预。

主要发现

  • 中危突变患者诊断时中位年龄42.3岁(范围6.4至86.4岁;均值41.6岁),高危突变患者23.0岁(范围3.7至66.8岁;均值25.6岁)(P < 0.0001)。
  • 中危患者诊断时T3/T4肿瘤更多(P = 0.03),但N或M分期无显著差异,总生存无显著差异(P = 0.40)。
  • 总生存多变量分析中,年龄增加(HR 1.05/年;95%CI 1.03至1.08)、T3/T4肿瘤(HR 2.73;95%CI 1.22至6.11)和诊断时M1状态(HR 3.93;95%CI 1.61至9.59)与更差总生存显著相关,高危突变则不显著(P = 0.40)。
  • 远处转移发生无显著差异(P = 0.33);远处转移多变量分析中仅诊断时N1状态显著(HR 2.10;95%CI 1.03至4.27)。

关键数值与推荐

  • 总生存多变量分析:年龄增加HR 1.05/年(95%CI 1.03至1.08)。
  • 总生存多变量分析:T3/T4肿瘤HR 2.73(95%CI 1.22至6.11)。
  • 总生存多变量分析:诊断时M1状态HR 3.93(95%CI 1.61至9.59)。
  • 远处转移多变量分析:诊断时N1状态HR 2.10(95%CI 1.03至4.27)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. OBJECTIVE: To determine whether high-risk RET mutations are more aggressive. DESIGN: Retrospective cohort study using institutional multiple endocrine neoplasia type 2 registry. SETTING: Tertiary cancer care center. PATIENTS: Patients with MTC and moderate- or high-risk germline RET mutation. INTERVENTION: None (observational study). MAIN OUTCOME MEASURES: Proxies for aggressiveness were overall survival (OS) and time to distant metastatic disease (DMD). RESULTS: A total of 127 moderate-risk and 135 high-risk patients were included (n = 262). Median age at diagnosis was 42.3 years (range, 6.4 to 86.4 years; mean, 41.6 years) for moderate-risk mutations and 23.0 years (range, 3.7 to 66.8 years; mean, 25.6 years) for high-risk mutations (P < 0.0001). Moderate-risk patients had more T3/T4 tumors at diagnosis (P = 0.03), but there was no significant difference for N or M stage and no significant difference in OS (P = 0.40). From multivariable analysis for OS, increasing age [hazard ratio (HR), 1.05/y; 95% confidence interval (CI), 1.03 to 1.08], T3/T4 tumor (HR, 2.73; 95% CI, 1.22 to 6.11), and M1 status at diagnosis (HR, 3.93; 95% CI, 1.61 to 9.59) were significantly associated with worse OS but high-risk mutation was not (P = 0.40). No significant difference was observed for development of DMD (P = 0.33). From multivariable analysis for DMD, only N1 status at diagnosis was significant (HR, 2.10; 95% CI, 1.03 to 4.27). CONCLUSIONS: Patients with high- and moderate-risk RET mutations had similar OS and development of DMD after MTC diagnosis and therefore similarly aggressive clinical courses. High-risk connotes increased disease aggressiveness; thus, future guidelines should consider RET mutation classification by disease onset (early vs late) rather than by risk (high vs moderate).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Voss RK, Feng L, Lee JE, et al. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017. PMID: 28609830. doi:10.1210/jc.2017-00317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。